CTLA4 and metastatic melanoma: Combined checkpoint inhibition with nivolumab (PD-1 inhibitor) and ipilimumab (CTLA-4 inhibitor) in metastatic melanoma has been extensively studied in multiple clinical trials (45–47, 56–71).